Six vaccine trials enhance post-dose booster Pfizer and Astrogenogen protection

• Randomized, double-blind test (patients randomly selected and unknown to teachers) 2,878 adults over 30;
• The researchers looked at the immune response, not the efficacy, although they were related; Namely: they checked whether the immune system was active against the virus, but did not estimate the rate of decrease in Govt cases in the vaccinated group compared to the non-vaccinated group;
• There are Seven vaccines tested As a reinforcement of Pfizer or AstraZeneca: Novavox, Johnson, Modernna, Valneva, Curaவாகao and again Pfizer or AstraZeneca.

During trials conducted in 2020, two doses of AstraZeneca and Pfizer showed 79% and 90% efficacy against hospitalization and mortality due to Covid-19, before being used in hundreds of countries. However, scientific evidence points out Safety was reduced a few months after the vaccination schedule was completed, Which justifies a booster size. So far, some studies have reported results of “extra” use.

• The United States needs a negative test one day before entering the country
• Germany imposes locks on those who do not vaccinate against Govt

“Side effect data showed it All vaccines are safe for booster dose., With acceptable levels of inflammatory events such as pain, muscle aches, and fatigue at the injection site, “said Saul Faust, research leader at the NHS-affiliated Foundation and director of the Center for Medical Research.

According to the scientist, the booster response after two doses of AstraZeneca increased in all trials with the 7 vaccines involved, varying from 1.8 to 32.3 times higher immunity.

• Micron: What do you know about the new variant
• Understand the rules: third dose, booster, vaccination schedule and passport

According to Pfizer, the results were positive for 6 vaccines, ranging from 1.3 to 11.5 times. Valeneva’s vaccine not only showed promising results for Pfizer, but the vaccine itself Is still under continuous review. The first step towards a formal application for authorization for use, through the European Pharmaceuticals Agency (EMA).

“It is important to note that these results only indicate the immune response they received after two primary applications of the booster vaccine and 28 days after the ‘extra dose’. Additional work will generate data three months and one year after receiving the booster. Brings new ‘insights’ into memory, “said Sol Fast.